RESUMEN
PURPOSE: To assess the reliability and reproducibility of static cyclotorsion correction (SCC) measurements made using the Schwind Amaris Excimer laser in patients undergoing LASIK or PRK, and compare the outcomes of treating astigmatism with and without SCC. METHODS: Eighty eyes of 40 patients were included in this study. All eyes underwent 2 or 3 sets of five measurements: before and after speculum placement, and after flap-lift (in LASIK cases). We assessed the reproducibility, accuracy, and the percentage of "no catch" measurements. The astigmatism was calculated pre-and 3-months-postoperatively by vector analysis. RESULTS: The mean age of the patients was 23.67 ã»} 4.19 years. Preoperative spherical equivalent and astigmatism were -2.56 ã»} 2.86 D and +1.36 ã»} 0.98 D, respectively. The mean measurement time was 15.1 seconds per measurement. The percentages of "no catch" were: 63.8%, 14.9%, and 26.9%; pre-speculum, post-speculum, and post flap-lift, respectively. Cyclotorsion of ≥}2° was seen in 41.25% and 66% of the cases before and after the flap-lift, respectively. Significant cyclotorsion (≥}5°) was seen in 12.50% and 18% of the eyes pre and post flap-lift. The mean astigmatism dropped from +1.53 D@1° to +0.34D@3° when SCC was used and from +1.86D@1° to +0.23D@7° when SCC was not used. No statistical difference was noticed between the groups (p>0.05) in the postoperative residual astigmatism. A postoperative astigmatism of ≥ D was seen in 10% and 20% of eyes with and without SCC, respectively (p<0.01). CONCLUSION: Although not always feasible, the SCC measurement is a simple and useful tool. Postoperative astigmatism showed less variability when SCC was used.
Asunto(s)
Astigmatismo/fisiopatología , Astigmatismo/cirugía , Queratomileusis por Láser In Situ/métodos , Láseres de Excímeros/uso terapéutico , Anomalía Torsional/fisiopatología , Anomalía Torsional/cirugía , Adulto , Córnea/cirugía , Femenino , Humanos , Masculino , Posicionamiento del Paciente , Estudios Prospectivos , Reproducibilidad de los Resultados , Colgajos Quirúrgicos , Factores de Tiempo , Resultado del Tratamiento , Agudeza Visual , Adulto JovenRESUMEN
Purpose: To assess the reliability and reproducibility of static cyclotorsion correction (SCC) measurements made using the Schwind Amaris Excimer laser in patients undergoing LASIK or PRK, and compare the outcomes of treating astigmatism with and without SCC. Methods: Eighty eyes of 40 patients were included in this study. All eyes underwent 2 or 3 sets of five measurements: before and after speculum placement, and after flap-lift (in LASIK cases). We assessed the reproducibility, accuracy, and the percentage of "no catch" measurements. The astigmatism was calculated pre-and 3-months-postoperatively by vector analysis. Results: The mean age of the patients was 23.67 ± 4.19 years. Preoperative spherical equivalent and astigmatism were -2.56 ± 2.86 D and +1.36 ± 0.98 D, respectively. The mean measurement time was 15.1 seconds per measurement. The percentages of "no catch" were: 63.8%, 14.9%, and 26.9%; pre-speculum, post-speculum, and post flap-lift, respectively. Cyclotorsion of ≥±2º was seen in 41.25% and 66% of the cases before and after the flap-lift, respectively. Significant cyclotorsion (≥±5º) was seen in 12.50% and 18% of the eyes pre and post flap-lift. The mean astigmatism dropped from +1.53 D@1º to +0.34D@3º when SCC was used and from +1.86D@1º to +0.23D@7º when SCC was not used. No statistical difference was noticed between the groups (p>0.05) in the postoperative residual astigmatism. A postoperative astigmatism of ≥1 D was seen in 10% and 20% of eyes with and without SCC, respectively (p<0.01). Conclusion: Although not always feasible, the SCC measurement is a simple and useful tool. Postoperative astigmatism showed less variability when SCC was used. .
Objetivo: Avaliar a confiabilidade e reprodutibilidade da correção da medida de ciclotorção estática (SCC), realizada com o excimer laser Schwind Amaris em pacientes submetidos a LASIK ou PRK, e comparar os resultados do tratamento de astigmatismo com e sem SCC. Método: Oitenta olhos (40 pacientes). Todos os olhos foram submetidos a 2 ou 3 séries de 5 medições: antes e após a colocação do espéculo, e depois do levantamento do flap (nos casos de LASIK). Foram avaliadas a reprodutibilidade, a precisão e a porcentagem de medições "não obtidas". O astigmatismo foi avaliado no pré-operatório e aos 3 meses de pós-operatório, por meio de análise vetorial. Resultados: A idade foi 23,67 ± 4,19 anos. O equivalente esférico e o astigmatismo pré-operatórios foram -2,56 ± 2,86 D, e 1,36 ± 0,98 D, respectivamente. O tempo de medição médio foi 15,1 segundos por medição; as porcentagens de medidas "não obtidas" foram: 63,8%, 14,9% e 26,9%; pré, pós-espéculo, e pós-levantamento do flap, respectivamente. Ciclotorção ≥±2º foi observada em 41,25% e 66 % dos casos pré e pós-levantamento do flap. Ciclotorção significativa (≥±5º) foi observada em 12,50% e 18% pré e pós-levantamento do flap. A média do astigmatismo diminuiu de 1,53D @ 1º para 0,34D @ 3º quando SCC foi usado e de 1,86D @ 1º a 0,23D @7º quando SCC não foi usado. O astigmatismo residual pós-operatório não foi estatisticamente diferente entre os grupos (p>0,05). O astigmatismo pós-operatório ≥1D foi observado em 10% e 20 % dos olhos com e sem SCC, respectivamente (p<0,01). Conclusão: A medição do SCC é fácil e útil, apesar de nem sempre ...
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Adulto Joven , Astigmatismo/fisiopatología , Astigmatismo/cirugía , Queratomileusis por Láser In Situ/métodos , Láseres de Excímeros/uso terapéutico , Anomalía Torsional/fisiopatología , Anomalía Torsional/cirugía , Córnea/cirugía , Láseres de Excímeros , Posicionamiento del Paciente , Estudios Prospectivos , Reproducibilidad de los Resultados , Colgajos Quirúrgicos , Factores de Tiempo , Resultado del Tratamiento , Agudeza VisualRESUMEN
PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.
Asunto(s)
Antibacterianos/uso terapéutico , Azitromicina/uso terapéutico , Blefaritis/tratamiento farmacológico , Soluciones Oftálmicas/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estadísticas no Paramétricas , Irrigación Terapéutica/métodos , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.
OBJETIVO: Avaliar a eficácia do uso tópico de azitromicina 1,5% no tratamento de blefarite crônica moderada a grave, comparando a eficácia de duas diferentes modalidades de tratamento. MÉTODOS: Um ensaio clínico randomizado incluiu 67 pacientes com blefarite anterior e/ou posterior crônica, acompanhados por três meses. Os sinais e sintomas foram classificados de acordo com a gravidade. Os pacientes foram randomizados em dois grupos: 33 pacientes no grupo I e 34 pacientes no grupo II. Os pacientes do grupo I foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias, e os pacientes do grupo II foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias e, em seguida, ao deitar, durante o resto do mês. Todos os pacientes foram instruídos a aplicarem compressas quentes e higiene palpebral duas vezes ao dia. RESULTADOS: Os pacientes em ambos os grupos toleraram o tratamento com irritação mínima. Melhora significativa dos sinais e sintomas foi observada na visita de uma semana de acompanhamento. Grupo II mostrou uma melhora mais acentuada e mais duradoura que persistiu após três meses de acompanhamento. CONCLUSÕES: A solução de azitromicina oftálmica tópica 1,5% é uma opção eficaz de tratamento para a blefarite crônica. Em blefarite moderada a grave, o tratamento de um mês é seguro e demonstrou melhora acentuada em relação ao protocolo de três dias, sem recidiva significante até três meses de acompanhamento.